Excel Industries Limited AI Stock Analysis
Want to see IN:EXCELINDUS full AI Analyst Report?
Excel Industries Limited (EXCELINDUS) AI Stock Analysis
Excel Industries Limited
(NSE:EXCELINDUS)
Excel Industries scores modestly above average. Its standout strength is a fortress balance sheet with virtually no debt and steadily compounding equity, which cushions the business through the specialty chemicals cycle. Offsetting this are inconsistent earnings — a sharp FY2024 downturn, a partial FY2025 recovery, and estimates pointing to renewed margin pressure in FY2026 — alongside deteriorating cash generation, with free cash flow falling to ₹183M and projected to turn negative amid heavy capex, plus weak cash conversion and low ROE. Technicals are supportive, with the price holding firmly above all key moving averages and a positive MACD, though momentum indicators are neutral, suggesting consolidation. Valuation at ~20x earnings is fair rather than compelling, with a modest 1.4% dividend yield. Investors should watch whether the current investment cycle lifts revenue, margins and cash conversion in coming years.
Excel Industries Limited (EXCELINDUS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 12.48B
- Dividend Yield
- 1.39%
- Average Volume (3M)
- 1,315
- Price to Earnings (P/E)
- 15.8
- Beta (1Y)
- 1.35
- Revenue Growth
- 5.79%
- EPS Growth
- 7.51%
- Country
- India
- Employees
- 1,162
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Excel Industries Limited Business Overview & Revenue Model
Company Description
Established in 1941 and headquartered in Mumbai, India, Excel Industries Limited conducts business both domestically and internationally, focusing on the production and sale of a diverse array of chemicals, pharmaceutical precursors, and ecological s...
How the Company Makes Money
Excel Industries Limited makes money primarily by selling chemicals it manufactures to industrial customers and other businesses. Key revenue streams are expected to include (a) sales of industrial and specialty chemical products to downstream indust...
Excel Industries Limited Financial Statement Overview
Summary
A very strong balance sheet (score 82) anchors the profile — near-zero debt (₹123M vs ₹15.9B equity), assets up from ₹11.1B to ₹19.2B and equity nearly doubling since FY2021 provide excellent resilience. However, the income statement (52) shows pronounced cyclicality: revenue fell from ₹11.7B in FY2022 to ₹8.3B in FY2024 with EBIT briefly negative, before recovering to ₹9.8B in FY2025 with an 8.7% net margin and record 48.2% gross margin; FY2026 estimates point to higher revenue but lower net income, implying margin compression. Cash flow (48) is the weakest link — FY2025 operating cash flow of ₹618M was the lowest in five years with a 0.36 cash conversion ratio, free cash flow slid to ₹183M and is estimated to turn negative in FY2026 on heavy capex. Low ROE of ~5.4% also suggests inefficient deployment of a large equity base.
Income Statement
52NeutralBalance Sheet
82Very PositiveCash Flow
48Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.83B | 10.95B | 9.78B | 8.26B | 10.84B | 11.72B |
| Gross Profit | 3.83B | 3.23B | 4.72B | 2.98B | 4.52B | 2.91B |
| EBITDA | 1.24B | 1.37B | 1.49B | 577.24M | 1.40B | 2.47B |
| Net Income | 790.79M | 756.65M | 853.13M | 170.10M | 799.36M | 1.61B |
Balance Sheet | ||||||
| Total Assets | 25.18B | 21.05B | 19.20B | 17.96B | 14.93B | 14.87B |
| Cash, Cash Equivalents and Short-Term Investments | 935.61M | 1.45B | 2.22B | 2.07B | 1.43B | 771.01M |
| Total Debt | 228.94M | 78.81M | 122.78M | 17.81M | 26.74M | 74.10M |
| Total Liabilities | 4.54B | 4.02B | 3.32B | 3.68B | 2.51B | 3.37B |
| Stockholders Equity | 20.64B | 17.03B | 15.89B | 14.27B | 12.42B | 11.49B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -33.68M | 182.70M | 404.65M | 926.92M | 350.40M |
| Operating Cash Flow | 0 | 761.00M | 618.19M | 723.73M | 1.25B | 1.09B |
| Investing Cash Flow | 0 | -493.62M | -412.90M | -512.29M | -1.18B | -1.04B |
| Financing Cash Flow | 0 | -245.01M | -160.70M | -169.31M | -345.81M | -168.89M |
Excel Industries Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EXCELINDUS, the sentiment is Positive. The current price of 989.25 is above the 20-day moving average (MA) of 900.52, above the 50-day MA of 931.71, and above the 200-day MA of 932.51, indicating a bullish trend. The MACD of 13.48 indicates Negative momentum. The RSI at 63.86 is Neutral, neither overbought nor oversold. The STOCH value of 87.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:EXCELINDUS.
Excel Industries Limited Peers Comparison
Overall Rating
IN:ALKYLAMINE67Neutral
IN:EXCELINDUS63Neutral
IN:BALAMINES57.5Neutral
IN:LXCHEM53Neutral
IN:NEOGEN50Neutral
IN:AARTIIND47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | INR 81.69B | 33.09 | ― | 0.63% | 13.38% | 35.82% | |
| 63Neutral | INR 12.44B | 15.76 | ― | 1.39% | 5.79% | 7.51% | |
| 58Neutral | INR 60.90B | 25.63 | ― | 0.59% | 20.91% | 62.44% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | INR 42.76B | 24.88 | ― | 0.19% | 21.34% | 105.39% | |
| 50Neutral | INR 80.34B | 178.99 | ― | 0.04% | 26.66% | 51.16% | |
| 47Neutral | INR 172.03B | 29.00 | ― | 0.21% | 39.85% | 103.71% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:EXCELINDUS | Excel Industries Limited | 989.25 | -22.68 | -2.24% | |
| IN:AARTIIND | AARTI Industries Ltd | 474.25 | 85.37 | 21.95% | |
| IN:ALKYLAMINE | Alkyl Amines Chemicals Limited | 1597.15 | -159.34 | -9.07% | |
| IN:BALAMINES | Balaji Amines Limited | 1879.45 | 691.68 | 58.23% | |
| IN:LXCHEM | Laxmi Organic Industries Ltd. | 153.85 | -30.19 | -16.40% | |
| IN:NEOGEN | Neogen Chemicals Ltd. | 2674.10 | 1369.98 | 105.05% |
Excel Industries Limited Corporate Events
Excel Industries Releases Q2 and H1 FY27 Investor Presentation
Excel Industries Limited is a backward-integrated specialty chemicals company serving markets through polymer inputs, pharmaceutical intermediaries, veterinary active pharmaceutical ingredients, and environment and biotechnology solutions. Establishe...
Excel Industries Opens Special Window for Transfer and Demat of Physical Shares
Excel Industries Limited, a Mumbai-headquartered chemical manufacturer with an Environment & Biotech Division, produces polymer inputs, pharmaceutical intermediaries and veterinary APIs. The firm’s BIS-backed ISO certifications across quality, enviro...
Excel Industries Closes Trading Window for Insiders Ahead of Q2 Results
Excel Industries Limited has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026 until 48 hours after the release of financial results for the quarter ended September 30, 2026. The res...
Excel Industries Earns Silver EcoVadis Rating, Bolstering Global Sustainability Credentials
Excel Industries Limited has received a Silver rating in the EcoVadis sustainability assessment, placing the company among the top 15 percent of businesses evaluated worldwide. The assessment covers environmental performance, labour and human rights,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026
